SENVELGO Best New Product Companion Animals award
SENVELGO won the 2023 Animal Health Best New Product for Companion Animals award
Search
2019 performance
Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
FDA-CRL-T1D
US FDA issues complete response letter for treatment of adults with type 1 diabetes
Mastitis dairy cows prevent antibiotic resistance
The Clinical and Laboratory Standards Institute (CLSI) approved revised interpretive criteria for the susceptibility testing of a mastitis product.
FRONTLINE® becomes Brand of the Year 2021-22
FRONTLINE® becomes Brand of the Year 2021-2022 in World Branding Awards
Questions and Answers
Answers to common questions from both patients and health care professionals regarding Compassionate Use of experimental medications.
NEJM-IL-36-Phase-1-GPP-data
Data published in The New England Journal of Medicine show rapid improvement of symptoms in patients with a rare form of pustular psoriasis
Uncommon_Mutations_Database
New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use
Collaboration to fight NCDs
70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.
FDA-Fast-Track-chronic-kidney-disease
FDA grants Fast Track designation for the treatment of chronic kidney disease, underscoring urgent need for new treatments for people living with the condition
GioTag Final Data
Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
Management Systems
Suppliers shall use management systems to support continuous improvement and compliance with the Supplier Code of Conduct.
survodutide top-line results MASH fibrosis
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
U.S. FDA grants priority review for spesolimab in GPP
U.S. FDA grants priority review for spesolimab in the treatment of patients with generalized pustular psoriasis
New indications NexGard, NexGard SPECTRA and Broadline
New therapeutic indications for NexGard®, NexGard SPECTRA® and Broadline® approved by EMA
Czech Republic
Czech Republic
InPedILD_trial_enrollment
First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
Koropi
For more than 45 years, the company has been producing pharmaceuticals in its production facility in Koropi, Greece.
We’re looking for SAP developers to join our Global IT Department
Are you looking to take the next step in your career? Our global IT department has new SAP developer positions available!
More Green Overview
Our pillar MORE GREEN encompasses environmental initiatives that consider many different aspects.
Perceived burden of COPD is higher for younger patients
New global survey reveals perceived burden of disease is greater in younger people living with COPD
new_analysis_nintedanib_SSc_ILD
Interim analysis results support long term treatment with nintedanib in SSc-ILD patients
Benefits & Rewards
We invest in our people so they will stay and grow with us. We offer benefits such as rewards and development opportunities to help retain employees.
CARMELINA-elderly-analysis
CARMELINA® outcome trial subgroup analysis demonstrates long-term cardiovascular and renal safety data in older people with type 2 diabetes
FDA accepts new chronic kidney disease treatment application
FDA accepts new chronic kidney disease treatment application